

# SSF Neurology Grand Rounds :: Disclosure Summary

## Thursday, July 14, 2022

*The following planners and presenters, in the past 24 months, have/had a financial relationship with an ineligible company: (S=Speaker; P=Planner)*

**Michael Elliott, M.D.** (P): Consultant: Amylyx (relationship ended)

**Christyn Edmundson, M.D.** (S): Advisor: Alexion; Speaker: Argenx; Consultant: Department of Defense (relationship ended)

*The following planners and presenters, in the past 24 months, have/had no financial relationship with an ineligible company:*

**Michael Doherty, M.D.**(P); **James Bowen, M.D.** (P); **Pravin Khemanl, M.D.** (P); **Linda Sahlin** (P)

**Purpose:** The information you provide addresses several requirements of the Accreditation Council for Continuing Medical Education (ACCME) to help **ensure independence** in CME activities. Everyone in a position to control the content of a CME activity must disclose all relevant financial relationships with an ineligible company to the CME provider. This information must be disclosed to participants prior to the beginning of the activity. Also, CME providers must mitigate current conflicts of interest prior to the educational activity.

**Definitions: “Financial relationships”** are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.

The ACCME defines a **“ineligible company”** as any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Among the exemptions to this definition are government organizations, non-health care related companies and non-profit organizations that do not advocate for ineligible companies.

Circumstances create a **“conflict of interest”** when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

ACCME focuses on financial relationships with ineligible companies in the 24-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines **“relevant financial relationships”** as financial relationships in any amount occurring within the past 24 months that create a conflict of interest.

**CME Activity Planning Committee Members:** If a conflict of interest exists, the Planning Committee member must withdraw from the Planning Committee unless the conflict can be mitigated. Mitigation may be made by one of the following methods: (1) Peer review of CME content will be conducted at another oversight level to assure no ineligible company bias exists; (2) Change in focus of course so the activity does not include information related to products or services about which the planning committee member has a conflict; (3) Severing relationship(s) between the member and any related ineligible company; (4) Others to be determined by SSF CME Committee.

**CME Activity Presenter:** When a conflict of interest exists, the Planning Committee must address the conflict by one of the following methods: (1) Review content to be presented by speaker in advance to assure content balance; (2) Change topic so the presentation is not related to products or services where a conflict exists; (3) Select a different presenter without any related ineligible company; (4) Include presentations by other faculty to provide an overall balance to the content of the course; (5) Limit or specify the sources for recommendations that the presenter can use. Each speaker is required to give a balanced, evidence-based presentation based on published research. No conclusions or recommendations without external validation may be made by a speaker with a conflict of interest.

# SSF Neurology Grand Rounds

## Thursday, July 14, 2022

### Featured Speaker

Christyn Edmundson, M.D.

### Presentation Title

Pearls & Pitfalls. Using Immunosuppressive Medications in Myasthenia Gravis

### Learning Objectives

- Outline established and novel immunotherapies used to treat myasthenia gravis
- Provide practical tips for safe prescribing and monitoring of immunotherapies in myasthenia gravis

### Agenda

- 7:30 a.m. Welcome and Introduction
- 7:31 a.m. Featured Presentation
- 8:20 a.m. Q & A
- 8:30 a.m. Adjourn

### Series Objectives

By attending this course, the participant will provide better patient care through an increased ability to:

- Identify and define the emerging technologies used in the treatment of neurological disorders
- Discuss new treatment modalities and diagnostic tools
- Apply new procedures for the diagnosis, treatment and management of neurological disorders

### Series Description

Multidisciplinary rounds, such as the Neurology Grand Rounds Series, bring healthcare professionals from different disciplines together to consider the diagnosis and treatment of specific patients. This series provides an opportunity for healthcare professionals to learn how other professionals approach medical issues and to interact with providers from different disciplines.

### Target Audience

Neurologists, neuroradiologists, neurosurgeons, primary care physicians, advanced practice clinicians and other sub-specialists in the treatment of neurological diseases in Washington, Oregon, Idaho, Montana, California and Alaska.

### Planning Committee

Michael Elliott, M.D.  
James Bowen, M.D.  
Pravin Khemani, M.D.  
Michael Doherty, M.D.  
Linda Sahlin, SSF

### Accreditation

Seattle Science Foundation (SSF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### AMA PRA Category 1 Credits™

SSF designates this live activity for a maximum of 24 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each session is designated for 1 AMA PRA Category 1 Credit™.

### Evaluation and Outcomes

At the end of each speaker session, attendees will complete a survey to evaluate the conference, list examples of concepts learned and describe ways in which the material presented will impact their practice.